Is Alnylam Pharmaceuticals (NASDAQ:ALNY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Alnylam Pharmaceuticals at current levels.
RNAi's first profitable platform company is trading near its 52-week low while its pipeline has never been broader or more valuable.
Where ALNY is headed
Alnylam Pharmaceuticals (NASDAQ:ALNY) just crossed a line that took two decades to reach: consistent profitability on the back of a platform that now has six approved drugs, with AMVUTTRA alone generating a revenue run-rate north of $2 billion annually. By late 2027, the company should be pulling in roughly $3.5 to $4 billion in total product revenue as Qfitlia (hemophilia) ramps through its first full commercial year, zilebesiran data in hypertension reads out from a massive outcomes trial, and the ATTR franchise continues compounding in wild-type patients who are only beginning to be diagnosed. The shift from money-burning biotech to cash-generating pharmaceutical company is not theoretical anymore; it happened in 2025, and the forward P/E of 21x tells you the market hasn't fully recalibrated to this new identity.
Read the full Compass Direction on ALNY
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $297.69).
See the full ALNY analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Alnylam Pharmaceuticals at current levels. RNAi's first profitable platform company is trading near its 52-week low while its pipeline has never been broader or more valuable.
What is ALNY's Compass Score?
Alnylam Pharmaceuticals scores 90/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ALNY?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ALNY page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.